Search
- Oct 27, 2022
Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+...
Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+ Relapsed/Refractory PTCL
561 views